Develops novel therapies for chronic inflammatory diseases using Monocyte Targeting Technology to block monocyte migration into inflamed tissues. The lead candidate, a monoclonal antibody, aims to provide a differentiated approach to treating conditions like Multiple Sclerosis and Rheumatoid Arthritis.